Literature DB >> 18480913

Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.

Robert F Anderson1, Sujata S Shinde, Andrej Maroz, Maruta Boyd, Brian D Palmer, William A Denny.   

Abstract

The reduction chemistry of the new anti-tuberculosis drug PA-824, together with a more water-soluble analogue, have been investigated using pulse and steady-state radiolysis in aqueous solution. Stepwise reduction of these nitroimidazo-dihydrooxazine compounds through electron transfer from the CO(2) (-) species revealed that, unlike related nitroimidazoles, 2-electron addition resulted in the reduction of the imidazole ring in preference to the nitro group. In mildly acidic solution a nitrodihydroimidazo intermediate was formed, which was reduced further to the amine product. In both alkaline and neutral solution, an intermediate produced on 2-electron reduction was resistant to further reduction and reverted to parent compound on extraction or mass spectrometric analysis of the solution. The unusual reduction chemistry of these nitroimidazole compounds, exhibiting ring over nitro group reduction, is associated with alkoxy substitution in the 2-position of a 4-nitroimidazole. The unique properties of the intermediates formed on the reduction of PA-824 need to be considered as playing a possible role in its bactericidal action.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480913     DOI: 10.1039/b801859f

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  6 in total

1.  Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Authors:  Rokeya Tasneen; Kathy Williams; Opokua Amoabeng; Austin Minkowski; Khisimuzi E Mdluli; Anna M Upton; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

2.  Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.

Authors:  M Dogra; B D Palmer; G Bashiri; M D Tingle; S S Shinde; R F Anderson; R O'Toole; E N Baker; W A Denny; N A Helsby
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824.

Authors:  Susan E Cellitti; Jennifer Shaffer; David H Jones; Tathagata Mukherjee; Meera Gurumurthy; Badry Bursulaya; Helena I Boshoff; Inhee Choi; Amit Nayyar; Yong Sok Lee; Joseph Cherian; Pornwaratt Niyomrattanakit; Thomas Dick; Ujjini H Manjunatha; Clifton E Barry; Glen Spraggon; Bernhard H Geierstanger
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

Review 4.  Nitroaromatic Antibiotics as Nitrogen Oxide Sources.

Authors:  Allison M Rice; Yueming Long; S Bruce King
Journal:  Biomolecules       Date:  2021-02-12

Review 5.  Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery.

Authors:  Divya Awasthi; Joel S Freundlich
Journal:  Trends Microbiol       Date:  2017-06-13       Impact factor: 17.079

6.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.